According to this report, the Global Vaccine Adjuvants market accounted for $460.21 million in 2017 and is expected to reach $1,330.25 million by 2026 growing at a CAGR of 12.5% from 2017 to 2026.
Some of the factors such as the high occurrence of zoonotic and infectious syndromes, growing geriatric population and rising usage of Adjuvants in Vaccine are fueling the market growth. However, factors such as the cost of adjuvant development and side effects of adjuvants are hampering the market growth. The rising usage of synthetic vaccines and recombinant sub-unit are acting as an opportunity for the market growth in the coming years.
Amongst Route of Administration, Intramuscular Route segment is driven by owing to rapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc.
By geography, North America region is dominated the market during the forecast period due to factors such as higher adoption, greater knowledge about regular vaccination and presence of major market players, coupled with higher healthcare expenditure.
Market share assessments for the regional and country level segmentsMarket share analysis of the top industry playersStrategic recommendations for the new entrantsMarket forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional marketsMarket Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)Strategic recommendations in key business segments based on the market estimationsCompetitive landscaping mapping the key common trendsCompany profiling with detailed strategies, financials, and recent developmentsSupply chain trends mapping the latest technological advancements
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
3.10 Futuristic Market Scenario
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
5 Global Vaccine Adjuvants Market, By Product
5.3 Particulate Adjuvants
5.4 Combination Adjuvants
6 Global Vaccine Adjuvants Market, By Disease Type
7 Global Vaccine Adjuvants Market, By Type
7.3 Tensoactive Adjuvants
7.5 Mineral Salt based Adjuvants
7.8 Carbohydrates Adjuvants
7.9 Bacteria-derived Adjuvants
8 Global Vaccine Adjuvants Market, By Mechanism of action
8.4 Active Immunostimulants
9 Global Vaccine Adjuvants Market, By Route of Administration
9.7 Other Route of Administrations
10 Global Vaccine Adjuvants Market, By Application
10.2 Veterinary Vaccine Adjuvants
10.3 Human Vaccine Adjuvants
11 Global Vaccine Adjuvants Market, By End User
11.3 Pharmaceutical Companies
11.4 Contract Manufacturing Organization
12 Global Vaccine Adjuvants Market, By Geography
12.4.7 Rest of Asia Pacific
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.5 Rest of Middle East & Africa
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.5 Other Key Strategies
14.4 Sigma Aldrich (Merck KGaA)
14.9 MVP Laboratories, Inc.
14.15 Avanti Polar Lipids
14.19 Adjuvance Technologies, Inc
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/21/2019 02:33 PM/DISC: 02/21/2019 02:33 PM
Copyright Business Wire 2019.